TapImmune Inc. to Sponsor Phase 1 Breast Cancer Vaccine Trial Following Recent FDA Approval of Investigational New Drug Application

SEATTLE and ROCHESTER, Minn., Aug. 11, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a leading biotechnology company developing immunotherapies, today announced that following FDA IND approval, it will sponsor a Phase I HER-2/neu targeted therapeutic vaccine trial in HER-2/neu positive breast cancer patients at the Mayo Clinic.

Back to news